Basic and clinical studies of SY5555 in respiratory infections

H. Fukuhara, J. Inadome, T. Kakazu, H. Nakamura, H. Kameshima, Y. Irabu, A. Saito, Nobuchika Kusano, I. Nakasone, F. Hurugen, S. Taira, S. Hokama, K. Shimoji, H. Ohshiro, H. Yogi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We performed a basic evaluation of SY5555, a newly developed oral penem antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity: The minimum inhibitory concentrations (MICs) of SY5555 against 280 strains of 12 species isolated from clinical material were measured and compared with those of the oral cephalosporins, cefaclor, cefotiam, cefixime and cefteram and the carbapenem, imipenem/cilastatin. SY5555 was more potent than the four cephalosporins against methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus milleri group, Enterococcus faecalis, Enterobacter cloacae, Acinetobacter calcoaceticus and Moraxella(Branhamella) catarrhalis, and was more active than cefotiam except against Escherichia coli. But SY5555 was less potent active than imipenemen/cilastatin except against S. pneumoniae, E. faecalis and Haemophilus influenzae and was not active against Pseudomonas aeruginosa, Serratia marcescens and methicillin-resistant S. aureus. 2. Clinical efficacy: SY5555 was given to 4 patients with pneumonia, 4 with chronic bronchitis and 4 with acute bronchitis, orally at 150-300 mg three times daily for 6-19 days. The clinical response was excellent in 1, good in 10 and fair in 1. No side effects were observed, but clinical laboratory tests showed slight elevation of GOT and GPT in one patient and slight elevation of GPT in another. From the above results, we consider SY5555 to be a useful antibiotic for the treatment of bacterial respiratory infections.

Original languageEnglish
Pages (from-to)406-412
Number of pages7
JournalChemotherapy
Volume42
Issue numberSUPPL. 1
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Respiratory Tract Infections
Cefotiam
Enterococcus faecalis
meropenem
Cephalosporins
Streptococcus pneumoniae
Streptococcus milleri Group
Cilastatin
Acinetobacter calcoaceticus
Cefixime
Staphylococcal Pneumonia
Cefaclor
Anti-Bacterial Agents
Moraxella (Branhamella) catarrhalis
Enterobacter cloacae
Serratia marcescens
Carbapenems
Methicillin
Bronchitis
Chronic Bronchitis

Keywords

  • SY5555

ASJC Scopus subject areas

  • Pharmacology

Cite this

Fukuhara, H., Inadome, J., Kakazu, T., Nakamura, H., Kameshima, H., Irabu, Y., ... Yogi, H. (1994). Basic and clinical studies of SY5555 in respiratory infections. Chemotherapy, 42(SUPPL. 1), 406-412.

Basic and clinical studies of SY5555 in respiratory infections. / Fukuhara, H.; Inadome, J.; Kakazu, T.; Nakamura, H.; Kameshima, H.; Irabu, Y.; Saito, A.; Kusano, Nobuchika; Nakasone, I.; Hurugen, F.; Taira, S.; Hokama, S.; Shimoji, K.; Ohshiro, H.; Yogi, H.

In: Chemotherapy, Vol. 42, No. SUPPL. 1, 1994, p. 406-412.

Research output: Contribution to journalArticle

Fukuhara, H, Inadome, J, Kakazu, T, Nakamura, H, Kameshima, H, Irabu, Y, Saito, A, Kusano, N, Nakasone, I, Hurugen, F, Taira, S, Hokama, S, Shimoji, K, Ohshiro, H & Yogi, H 1994, 'Basic and clinical studies of SY5555 in respiratory infections', Chemotherapy, vol. 42, no. SUPPL. 1, pp. 406-412.
Fukuhara H, Inadome J, Kakazu T, Nakamura H, Kameshima H, Irabu Y et al. Basic and clinical studies of SY5555 in respiratory infections. Chemotherapy. 1994;42(SUPPL. 1):406-412.
Fukuhara, H. ; Inadome, J. ; Kakazu, T. ; Nakamura, H. ; Kameshima, H. ; Irabu, Y. ; Saito, A. ; Kusano, Nobuchika ; Nakasone, I. ; Hurugen, F. ; Taira, S. ; Hokama, S. ; Shimoji, K. ; Ohshiro, H. ; Yogi, H. / Basic and clinical studies of SY5555 in respiratory infections. In: Chemotherapy. 1994 ; Vol. 42, No. SUPPL. 1. pp. 406-412.
@article{5c673ce8a7c64c3885dfada203c0e3d5,
title = "Basic and clinical studies of SY5555 in respiratory infections",
abstract = "We performed a basic evaluation of SY5555, a newly developed oral penem antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity: The minimum inhibitory concentrations (MICs) of SY5555 against 280 strains of 12 species isolated from clinical material were measured and compared with those of the oral cephalosporins, cefaclor, cefotiam, cefixime and cefteram and the carbapenem, imipenem/cilastatin. SY5555 was more potent than the four cephalosporins against methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus milleri group, Enterococcus faecalis, Enterobacter cloacae, Acinetobacter calcoaceticus and Moraxella(Branhamella) catarrhalis, and was more active than cefotiam except against Escherichia coli. But SY5555 was less potent active than imipenemen/cilastatin except against S. pneumoniae, E. faecalis and Haemophilus influenzae and was not active against Pseudomonas aeruginosa, Serratia marcescens and methicillin-resistant S. aureus. 2. Clinical efficacy: SY5555 was given to 4 patients with pneumonia, 4 with chronic bronchitis and 4 with acute bronchitis, orally at 150-300 mg three times daily for 6-19 days. The clinical response was excellent in 1, good in 10 and fair in 1. No side effects were observed, but clinical laboratory tests showed slight elevation of GOT and GPT in one patient and slight elevation of GPT in another. From the above results, we consider SY5555 to be a useful antibiotic for the treatment of bacterial respiratory infections.",
keywords = "SY5555",
author = "H. Fukuhara and J. Inadome and T. Kakazu and H. Nakamura and H. Kameshima and Y. Irabu and A. Saito and Nobuchika Kusano and I. Nakasone and F. Hurugen and S. Taira and S. Hokama and K. Shimoji and H. Ohshiro and H. Yogi",
year = "1994",
language = "English",
volume = "42",
pages = "406--412",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Basic and clinical studies of SY5555 in respiratory infections

AU - Fukuhara, H.

AU - Inadome, J.

AU - Kakazu, T.

AU - Nakamura, H.

AU - Kameshima, H.

AU - Irabu, Y.

AU - Saito, A.

AU - Kusano, Nobuchika

AU - Nakasone, I.

AU - Hurugen, F.

AU - Taira, S.

AU - Hokama, S.

AU - Shimoji, K.

AU - Ohshiro, H.

AU - Yogi, H.

PY - 1994

Y1 - 1994

N2 - We performed a basic evaluation of SY5555, a newly developed oral penem antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity: The minimum inhibitory concentrations (MICs) of SY5555 against 280 strains of 12 species isolated from clinical material were measured and compared with those of the oral cephalosporins, cefaclor, cefotiam, cefixime and cefteram and the carbapenem, imipenem/cilastatin. SY5555 was more potent than the four cephalosporins against methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus milleri group, Enterococcus faecalis, Enterobacter cloacae, Acinetobacter calcoaceticus and Moraxella(Branhamella) catarrhalis, and was more active than cefotiam except against Escherichia coli. But SY5555 was less potent active than imipenemen/cilastatin except against S. pneumoniae, E. faecalis and Haemophilus influenzae and was not active against Pseudomonas aeruginosa, Serratia marcescens and methicillin-resistant S. aureus. 2. Clinical efficacy: SY5555 was given to 4 patients with pneumonia, 4 with chronic bronchitis and 4 with acute bronchitis, orally at 150-300 mg three times daily for 6-19 days. The clinical response was excellent in 1, good in 10 and fair in 1. No side effects were observed, but clinical laboratory tests showed slight elevation of GOT and GPT in one patient and slight elevation of GPT in another. From the above results, we consider SY5555 to be a useful antibiotic for the treatment of bacterial respiratory infections.

AB - We performed a basic evaluation of SY5555, a newly developed oral penem antibiotic, and clinically studied its application in the treatment of respiratory infections, with the following results. 1. Antibacterial activity: The minimum inhibitory concentrations (MICs) of SY5555 against 280 strains of 12 species isolated from clinical material were measured and compared with those of the oral cephalosporins, cefaclor, cefotiam, cefixime and cefteram and the carbapenem, imipenem/cilastatin. SY5555 was more potent than the four cephalosporins against methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus milleri group, Enterococcus faecalis, Enterobacter cloacae, Acinetobacter calcoaceticus and Moraxella(Branhamella) catarrhalis, and was more active than cefotiam except against Escherichia coli. But SY5555 was less potent active than imipenemen/cilastatin except against S. pneumoniae, E. faecalis and Haemophilus influenzae and was not active against Pseudomonas aeruginosa, Serratia marcescens and methicillin-resistant S. aureus. 2. Clinical efficacy: SY5555 was given to 4 patients with pneumonia, 4 with chronic bronchitis and 4 with acute bronchitis, orally at 150-300 mg three times daily for 6-19 days. The clinical response was excellent in 1, good in 10 and fair in 1. No side effects were observed, but clinical laboratory tests showed slight elevation of GOT and GPT in one patient and slight elevation of GPT in another. From the above results, we consider SY5555 to be a useful antibiotic for the treatment of bacterial respiratory infections.

KW - SY5555

UR - http://www.scopus.com/inward/record.url?scp=0028239697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028239697&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028239697

VL - 42

SP - 406

EP - 412

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 1

ER -